Strategic report Governance & remuneration Financial statements Investor information Corporate governance continued The Nominations Committee reviewed the register of potential Directors conict authorisations in January 2016 and reported to the Board Our Directors powers are determined by UK legislation and our that the conicts had been appropriately authorised and that the Articles of Association, which contain rules about the appointment process for authorisation continues to operate effectively.
Except and replacement of Directors.
They provide that Directors may be as described in Note 35 to the financial statements, Related party appointed by an ordinary resolution of the members or by a transactions, during or at the end of the financial year no Director resolution of the Directors, provided that, in the latter instance, or connected person had any material interest in any contract of a Director appointed in this way retires at the first AGM following signicance with a Group company.
Independent advice Our Articles also provide that Directors should normally be subject The Company has an agreed procedure for Directors to take to re-election at the AGM at intervals of three years or annually if independent legal and or financial advice at the companys they have held ofce for a continuous period of nine years or more.
expense where they deem it necessary.
However, the Board agreed in 2011 that all Directors who wish to indemnification of Directors continue as members of the Board should seek re-election Qualifying third party indemnity provisions as dened in the annually in accordance with the UK Corporate Governance Code.
Companies Act 2006 are in force for the benefit of Directors and A Director may cease to be a Director if he or she: former Directors who held ofce during 2015 and up to the signing of the Annual Report.
becomes bankrupt ceases to be a Director by virtue of the Companies Change of control and essential contracts Act or the Articles We do not have contracts or other arrangements which individually suffers mental or physical ill health and the Board resolves are fundamental to the ability of the business to operate effectively, that he or she shall cease to be a Director nor is the company party to any material agreements that would take has missed Directors meetings for a continuous period of six effect, be altered, or terminate upon a change of control following months without permission and the Board resolves that he or a takeover bid.
We do not have agreements with any Director that she shall cease to be a Director would provide compensation for loss of ofce or employment resulting from a takeover, except that provisions of the companys is prohibited from being a Director by law share plans may cause options and awards granted under such resigns, or offers to resign and the Board accepts that offer plans to vest on a takeover.
Details of the termination provisions in is required to resign by the Board the companys framework for contracts for Executive Directors are Directors conicts of interest given in the full version of the companys remuneration policy report All Directors have a duty under the Companies Act 2006 to avoid a which is available at www.
com in the Investors section.
situation in which they have, or could have, a direct or indirect conict of interest or possible conict with the company.
Our Articles provide a general power for the Board to authorise such conicts.
The Nominations Committee has been authorised by the Board to grant and regularly review any potential or actual conict authorisations, which are recorded by the Company Secretary and noted by the Board.
Directors are not counted in the quorum for the authorisation of their own actual or potential conicts.
On an ongoing basis, the Directors are responsible for informing the Company Secretary of any new actual or potential conicts that may arise or if there are any changes in circumstances that may affect an authorisation previously given.
Even when provided with authorisation, a Director is not absolved from his or her statutory duty to promote the success of the company.
If an actual conict arises post-authorisation, the Board may choose to exclude the Director from receipt of the relevant information and participation in the debate, or suspend the Director from the Board, or, as a last resort, require the Director to resign.
100 GSK Annual Report 2015 Strategic report Governance & remuneration Financial statements Investor information Directors continued Directors Report For the purposes of the UK Companies Act 2006, the Directors Report of GlaxoSmithKline plc for the year ended 31 December 2015 comprises pages 73 to 101 of the Corporate Governance Report, the Directors Responsibility Statements on pages 130 and 211 and pages 231 to 258 of Investor Information.
The Strategic report sets out those matters required to be disclosed in the Directors Report which are considered to be of strategic importance to the company, as follows: risk management objectives and policies pages 16, 17 and 72 likely future developments of the company throughout the Strategic report research and development activities pages 18 to 31 diversity and inclusion page 47 provision of information to, and consultation with, employees page 46 carbon emissions page 48 The following information is also incorporated into the Directors Report: Location in Annual Report Financial statements, Interest capitalised Notes 17 and 19 Publication of unaudited financial information Group financial review, page 51 Details of any long-term incentive schemes Remuneration report Waiver of emoluments by a Director Not applicable Waiver of future emoluments by a Director Not applicable Non pre-emptive issues of equity for cash Not applicable Non pre-emptive issues of equity for cash Not applicable by any unlisted major subsidiary undertaking Parent company participation in a placing Not applicable by a listed subsidiary Provision of services by a controlling Not applicable shareholder Financial statements, Shareholder waiver of dividends Notes 15 and 42 Financial statements, Shareholder waiver of future dividends Notes 15 and 42 Agreements with controlling shareholders Not applicable The Directors Report has been drawn up and presented in accordance with and in reliance upon English company law and the liabilities of the Directors in connection with that report shall be subject to the limitations and restrictions provided by such law.
The Directors Report was approved by the Board of Directors on 16 March 2016 and signed on its behalf by: Philip Hampton Chairman 16 March 2016 GSK Annual Report 2015 101
